NRx Pharmaceuticals (NRXP)
(Delayed Data from NSDQ)
$2.08 USD
+0.04 (1.96%)
Updated Aug 23, 2024 03:59 PM ET
After-Market: $2.08 0.00 (0.00%) 7:58 PM ET
2-Buy of 5 2
F Value A Growth C Momentum C VGM
Cash flow Statements
Fiscal Year End for NRx Pharmaceuticals, Inc falls in the month of December.
All data in Millions except Per Share data.
Cash Flow From Operations, Investments & Financial Activities
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Cash Flow From Operations, Investments & Financial Activities |
|||||
Net Income (Loss) | -30.15 | -39.75 | -93.06 | -0.43 | 0.41 |
Depreciation/Amortization & Depletion | 0.01 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Change from Assets/Liabilities | 5.16 | 0.70 | -4.90 | 0.33 | 0.00 |
Net Cash from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Operating Activities | 3.32 | -0.70 | 60.26 | -0.49 | -1.21 |
Net Cash From Operating Activities | -21.66 | -39.76 | -37.70 | -0.60 | -0.79 |
Property & Equipment | 0.00 | -0.01 | -0.01 | 0.00 | 0.00 |
Acquisition/ Disposition of Subsidiaries | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Investments | 0.00 | 0.00 | 0.00 | -0.28 | -0.99 |
Other Investing Activities | 0.00 | 0.00 | 0.00 | 26.46 | 41.24 |
Net Cash from Investing Activities | 0.00 | -0.01 | -0.01 | 26.18 | 40.25 |
Uses of Funds
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Issuance (Repurchase) of Capital Stock | 9.29 | 22.71 | 53.68 | -26.30 | -40.73 |
Issuance (Repayment) of Debt | -3.09 | 9.50 | -0.18 | 0.72 | 1.26 |
Increase (Decrease) Short-Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Payment of Dividends & Other Distributions | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Financing Activities | 0.00 | 0.00 | 9.95 | 0.00 | 0.00 |
Net Cash from Financing Activities | 6.20 | 32.21 | 63.46 | -25.58 | -39.46 |
Effect of Exchange Rate Changes | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Change In Cash & Equivalents | -15.46 | -7.55 | 25.75 | 0.00 | -0.01 |
Cash at Beginning of Period | 20.05 | 27.61 | 1.86 | 0.00 | 0.01 |
Cash at End of Period | 4.60 | 20.05 | 27.61 | 0.00 | 0.00 |
Diluted Net EPS | -4.00 | -6.00 | -74.40 | -1.60 | -1.10 |
Fiscal Year End for NRx Pharmaceuticals, Inc falls in the month of December.
All data in Millions except Per Share data.
Cash Flow From Operations, Investments & Financial Activities
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
---|---|---|---|---|---|
Cash Flow From Operations, Investments & Financial Activities |
|||||
Net Income (Loss) | -14.43 | -6.53 | -30.15 | -25.82 | -19.76 |
Depreciation/Amortization & Depletion | 0.00 | 0.00 | 0.01 | 0.00 | 0.00 |
Net Change from Assets/Liabilities | 4.39 | 2.29 | 5.16 | 2.74 | 1.93 |
Net Cash from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Operating Activities | 3.80 | 0.57 | 3.32 | 4.61 | 3.92 |
Net Cash From Operating Activities | -6.23 | -3.67 | -21.66 | -18.47 | -13.90 |
Property & Equipment | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Acquisition/ Disposition of Subsidiaries | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Investments | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Investing Activities | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Cash from Investing Activities | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Uses of Funds
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
---|---|---|---|---|---|
Issuance (Repurchase) of Capital Stock | 5.69 | 2.55 | 9.29 | 9.29 | 8.12 |
Issuance (Repayment) of Debt | -2.16 | -2.16 | -3.09 | -1.98 | 0.70 |
Increase (Decrease) Short-Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Payment of Dividends & Other Distributions | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Financing Activities | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Cash from Financing Activities | 3.54 | 0.40 | 6.20 | 7.32 | 8.82 |
Effect of Exchange Rate Changes | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Change In Cash & Equivalents | -2.70 | -3.28 | -15.46 | -11.15 | -5.09 |
Cash at Beginning of Period | 4.60 | 4.60 | 20.05 | 20.05 | 20.05 |
Cash at End of Period | 1.90 | 1.32 | 4.60 | 8.90 | 14.97 |
Diluted Net EPS | -0.75 | -0.74 | -0.50 | -0.70 | -1.20 |